Table 1.
Characteristics of the included studies
| Author | Year | Country | Trial phase | Patient no. (T/C) | Median ages (T/C, years) | Female (T/C, %) | EGFR mutation (%) | Treatment group | Treatment pattern | Control group | Outcomes | Study quality |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pesce | 2012 | Switzerland | II | 16/43 | 57/63 | 44.0/37.0 | NA | WBRT+gefitinib | Concurrent | WBRT+TMZ | mOS | B |
| Fu | 2012 | China | NA | 38/123 | NA | NA | NA | WBRT/SRS+gefitinib | Concurrent | WBRT/SRS | ORR | C |
| Zeng | 2012 | China | NA | 45/45 | 56/52 | 57.8/53.3 | NA | WBRT+gefitinib | Concurrent | Gefitinib | RR, DCR, mTTP, mPFS, mOS | B |
| Wu | 2012 | China | NA | 35/18 | NA | NA | NA | WBRT+gefitinib | Concurrent | WBRT | RR, DCR, mOS | B |
| Cai | 2013 | China | NA | 65/92 | NA | 38.5/31.5 | 27.4 | WBRT+gefitinib/erlotinib | Concurrent | WBRT | RR, DCR, mPFS, mOS | B |
| Sperduto | 2013 | Multicenter | III | 41/44 | 61/64 | NA | NA | WBRT+SRS+erlotinib | Concurrent | WBRT/SRS | CNS‐TTP, mOS | B |
| Zhuang | 2013 | China | II | 23/31 | 60/63 | 57/58 | 20.4 | WBRT+erlotinib | Concurrent | WBRT | ORR, CNS‐TTP, PFS, mOS | B |
| Liu | 2013 | China | NA | 52/52 | 54/51 | 44.2/48.1 | NA | WBRT+SRS+gefitinib/erlotinib | Concurrent | WBRT+SRS | RR, DCR, PFS | C |
| Zhou | 2013 | China | NA | 36/22 | NA | 58.3/50.0 | NA | WBRT+gefitinib/erlotinib | Concurrent | WBRT+chemotherapy | RR, DCR, mOS | C |
| Fan | 2013 | China | NA | 75/111 | 57/57 | 42.7/27.0 | NA | WBRT/SRS+TKI | Sequential | WBRT/SRS+chemotherapy | mOS | B |
| Lee | 2014 | Britain | II | 40/40 | 61/62 | 62.5/47.5 | 2.9 | WBRT+erlotinib | Concurrent | WBRT+placebo | CNS‐TTP, mOS | B |
| Cai | 2014 | China | NA | 104/178 | 65/65 | 40.4/33.7 | 19.50% | WBRT/SRS+TKI | Sequential | WBRT/SRS | CNS‐TTP, mOS | B |
| Wang | 2015 | China | NA | 37/36 | 61/62 | 32.4/36.1 | 12.30% | 3D‐CRT+gefitinib | Concurrent | 3D‐CRT+chemotherapy | ORR, mOS | B |
| Liu | 2015 | China | NA | 35/15 | 46.3/47.5 | 51.4/53.3 | NA | WBRT+gefitinib | Concurrent | WBRT+chemotherapy | RR, DCR, mOS | C |
| Chen | 2015 | China | NA | 30/30 | 64.5/64.3 | 46.7/50.0 | NA | WBRT+gefitinib | Concurrent | WBRT+chemotherapy | RR, DCR, PFS, mOS | B |
T/C, treatment/control; ECOG PS, eastern cooperative oncology group performance status; NA, not applicable; RR, response rate; DCR, disease control rate; TTP, time to progression; PFS, progression‐free survival; OS, overall survival; WBRT, whole brain radiotherapy; SRS, stereotactic radiosurgery; CNS, central nervous system; 3D‐CRT, three‐dimensional conformal radiotherapy; TMZ, temozolomide.